Satellos Bioscience (MSLE) EBITDA (2025 - 2026)

Satellos Bioscience's (MSLE) quarterly EBITDA came in at -$9.7 million in Q1 2026, down 260.17% year-on-year from $6.1 million in Q1 2025, and down 260.17% on a QoQ basis from $6.1 million in Q1 2025.

Satellos Bioscience (MSLE) EBITDA (2025 - 2026) Analysis & Trends

Satellos Bioscience (MSLE) has 2 years of EBITDA data on file, last reported at -$9.7 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -27.75 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 249.90 Mn
4 NuCana 279.75 Bn 279.75 Bn - -3.72 Mn
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 1.14 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 642.90 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -32.68 Mn
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 493.00 Mn
9 Revolution Medicines 37.78 Bn 37.78 Bn - -445.22 Mn
10 Satellos Bioscience 148.71 Mn 148.71 Mn - -9.74 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -9.74 Mn
Mar 31, 2025 6.08 Mn